Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China.

@article{Liang2011SafetyOI,
  title={Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China.},
  author={Xiao-feng Liang and Li Li and Da-wei Liu and Ke-li Li and Wen-di Wu and Bao-Ping Zhu and Huaqing Wang and Hui-ming Luo and Ling-sheng Cao and Jing-shan Zheng and Da-peng Yin and Lei Cao and Bing-bing Wu and Hongzhe Bao and Disha Xu and Weizhong Yang and Yu Wang},
  journal={The New England journal of medicine},
  year={2011},
  volume={364 7},
  pages={
          638-47
        }
}
BACKGROUND On September 21, 2009, China began administering vaccines, obtained from 10 different manufacturers, against 2009 pandemic influenza A (H1N1) virus infection in priority populations. [] Key Method Physicians or vaccination providers were required to report the numbers of vaccinees and all adverse events to their local Center for Disease Control and Prevention (CDC), which then reported the data to the Chinese CDC through the online National Immunization Information System's National Adverse Event…

Figures and Tables from this paper

Incidence of Adverse Events Among Healthcare Workers Following H1N1 Mass Immunization in Ghana
TLDR
The most prominent adverse events reported were headaches, dizziness, muscle and joint aches, weakness, fever and injection-site pain, which was recorded as the most frequent in the SPC and other foreign studies.
Safety of measles-containing vaccines in post-marketing surveillance in Anhui, China
TLDR
This study presents up-to-date data and suggests that the measles-containing vaccines used in Anhui Province of China are safe.
Clinical Assessment of Serious Adverse Events in Children Receiving 2009 H1N1 Vaccination
TLDR
Most AEFI in children evaluated were not causally related to vaccine and resolved without sequelae, and detailed clinical assessment of individual serious AEFI can provide reassurance of vaccine safety.
Surveillance of adverse events following H1N1/09 influenza immunisation in Victoria, Australia
TLDR
There was a TIV brand specific [Fluvax?] increase in febrile convulsions post vaccination in Australian states in 2010, and this vaccine is no longer licensed for children <5 years of age.
Adverse events with the influenza A(H1N1) vaccine Pandemrix® at healthcare professionals in Portugal.
TLDR
An acceptable safety profile of this pandemic flu vaccine among healthcare professionals is suggested, both frequency and severity of the observed adverse event following immunization do not seem to be higher than expected.
Comparison of adverse events following immunization with pandemic influenza A (H1N1)pdm09 vaccine with or without adjuvant among health professionals in Rio de Janeiro, Brazil.
TLDR
It is concluded that the two types of vaccines caused no serious AEFI in the studied population and the adjuvanted vaccine was more reactogenic, particularly in the 24 h following vaccination.
Spontaneous reporting of adverse events following pandemic influenza A (H1N1) immunization in a reference center in the State of São Paulo, Brazil.
TLDR
Adverse events (AEs) temporally associated to the pandemic influenza A (H1N1) vaccine observed in a reference center in São Paulo, Brazil, during a 2010 mass vaccination campaign are described.
...
...

References

SHOWING 1-10 OF 20 REFERENCES
A novel influenza A (H1N1) vaccine in various age groups.
TLDR
These data suggest that a single dose of 15 microg of hemagglutinin antigen without alum adjuvant induces a typically protective immune response in the majority of subjects between 12 and 60 years of age.
Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.
TLDR
Monovalent 2009 influenza A (H1N1) MF59-adjuvanted vaccine generates antibody responses likely to be associated with protection after a single dose is administered.
Response to a monovalent 2009 influenza A (H1N1) vaccine.
TLDR
A single 15-microg dose of 2009 H1N1 vaccine was immunogenic in adults, with mild-to-moderate vaccine-associated reactions.
Study on the Surveillance of Adverse Events Following Immunization in China,2005-2006
TLDR
The pilot study shows that the safety of NIP vaccines and the quality of immunization services are satisfactory, and the timeliness of surveillance needs to be improved.
[Analysis on the surveillance of adverse events following immunization in China, 2007-2008].
TLDR
The completeness and sensitivity of national AEFI surveillance system were improved greatly in 2007-2008, but it still needs to be strengthened, and the NIP vaccines were significantly related to the introduced vaccines in Expanded Immunization Program.
Adverse events reported following live, cold-adapted, intranasal influenza vaccine.
TLDR
Reports to VAERS in the first 2 seasons of LAIV-T use did not identify any unexpected serious risks with this vaccine when used according to approved indications, and like many vaccines and other medical products, LAiv-T may rarely cause anaphylaxis.
Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977.
Because of an increase in the number of reports of Guillian-Barre syndrome (GBS) following A/New Jersey influenza vaccination, the National Influenza Immunization Program was suspended December 16,
The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines.
TLDR
There was no increase in the risk of vaccine-associated Guillain-Barré syndrome from 1992-1993 to 1993-1994 and for the two seasons combined, the adjusted relative risk of 1.7 suggests slightly more than one additional case of Guillian-B Barré syndrome per million persons vaccinated against influenza.
...
...